Aging, Chronic Diseases, and the Rise of Self-Care

I am in my 40s and live in Western Europe. Last year, my parents reached retirement age. That moment pushed me to reflect on today’s realities. To be fair, very few of my peers ever stop to think about what retirement will look like in 30 years. By then, our population will look very different as Europe is aging fast. Projections show that fewer than two working-age adults will be left to support each older person. The median age will rise sharply too, which will cause the prevalence of age-related chronic conditions to grow dramatically. Experts draw many scenarios. Even the most optimistic ones show our healthcare and social systems will be stretched thin. Yet I am an optimist by nature. I believe we will adapt. We simply have no other choice. Advances in telemedicine, AI-driven healthcare, and self-care tools (from smart pills to connected autoinjectors) can change how we retire. Let’s discuss how that optimistic future could look if we start adapting today

Understanding the Aging Shift in the Global West

Today, 22% of the EU’s 450.6 million people are already 65 or older. The old-age dependency ratio stands at 34.5%, meaning just over three working-age people support every person aged 65 and above. In 30 years, projections show that ratio climbing to around 55–60% by 2050 according to Eurostat (1). The median age will reach about 48–50 years by mid-century and people aged 85 and over will more than double in many areas. Inevitably, we will have to work longer and retire later than our parents did. Many EU countries are already raising statutory retirement ages, with OECD projections indicating that some nations will have to push retirement age toward 70 or more in response to these demographic pressures (2). This shift is only possible if we stay healthier for longer.

We often fear growing older, yet there is a surprising twist ahead: with better health and a calmer mind, many of us may actually enjoy working longer and find our later years freer and happier than we imagine today.

Chronic Diseases Dominate Later Life

Let’s face this reality head on. Aging brings more chronic illnesses. Currently, more than 65% of Europeans aged 65 and over live with multiple chronic conditions (multimorbidity) (3). Common issues include high blood pressure, arthritis, back problems, diabetes, cardiovascular diseases, chronic obstructive pulmonary disease, depression, and dementia. As populations age, the total health and economic cost of non-communicable diseases in the EU is projected to increase by over 70% by 2050 (4). Many of these conditions require lifelong management at home. This approach eases hospital loads and gives patients greater autonomy.

Researchers and industry see it the same way. Recent European studies show that AI-powered telemedicine and connected self-care devices can reduce hospital admissions by up to 48% and shorten hospital stays by 63% in older adults with multiple conditions (5). Wearable sensors and remote monitoring tools improve daily adherence and truly enable self-management from home. Even though I’m still relatively young, it’s hard to picture myself relying on these devices every day. Still, I’d rather start learning about them now than scramble to figure it out when I’m older and need them most.

Companies and startups clearly understand the growing need for smarter, home-based tools to manage aging and chronic conditions. This is evidenced by strong investment momentum and a rising number of innovative players: U.S. digital health startups raised $14.2 billion in 2025 (a 35% increase from 2024, per Rock Health), with global funding reaching around $22–28 billion across reports, and AI-enabled solutions capturing 50–54% of deals and funding.

Self-Care: The Future of Managing Chronic Conditions

Mens sana in corpore sano (Lat. "a healthy mind in a healthy body") — that old Latin saying still rings true. Yet years of yoga or weekly runs in our younger days cannot restore failing organs or repair worn-out joints. The reality is clear: most of us will eventually need to live with and actively manage chronic conditions, whether through oral medications or injectables. Many of these can already be handled safely at home, often using autoinjectors — specialized MedTech devices designed for self-administration of biologics. Common examples include rheumatoid arthritis, treated with biologics such as adalimumab or etanercept, self-injected weekly or biweekly.

Self-care extends well beyond injections. It also encompasses daily pills for hypertension, statins for cholesterol control, or oral antidiabetics. Still, autoinjectors stand out for biologics and hormones: they are user-friendly for aging hands, minimize pain and anxiety, and restore a sense of control. I can picture myself in my seventies with stiff, aching joints — no more tiring trips to the clinic. Instead, I load a cartridge into an electromechanical autoinjector, follow the on-screen instructions, select a comfortable injection speed, and let the device log the dose, send reminders, and track adherence.

This delivery method is growing increasingly attractive. Pharmaceutical companies are rapidly expanding their pipelines of subcutaneous biologics, with more than 175 already approved worldwide and over 340 in clinical development (6). Analyses of FDA novel drug approvals over the past decade show that approximately 12–15% are for drugs that cannot be administered orally and require injection. This share is poised to rise to 20–30% over the next 10–20 years (7). The progression from expanding pipelines and to current approval statistics creates a clear, evidence-based narrative of why autoinjector-based delivery is set to become even more prevalent.

The true advantage lies in integration: connected autoinjectors link seamlessly into a broader ecosystem with wearables and AI-powered telemedicine platforms. Injection data flows automatically to monitoring tools and physician dashboards, offering real-time insights into adherence, side effects, and disease trends — enabling faster adjustments without routine visits.

Evidence strongly supports this model. Connected devices routinely achieve adherence rates of 90% or higher — well above the typical 50–70% for standard oral or injectable therapies. Improved adherence leads to better disease control, reduced overall costs, and greater sustainability via reusable hardware.

Without integrated self-care solutions like connected autoinjectors, wearables, and AI telemedicine, healthcare systems will face growing strain: hospitals could become overwhelmed, costs would rise significantly, and patient outcomes might suffer. With these tools in place, self-care can scale effectively, give individuals greater control over their health, and align well with the realities of aging populations and smaller workforces.

Questions We Must Answer

We need to start asking uncomfortable questions and bring them into public and political discussions. How do we prepare people for self-care? Should we teach basic device skills early? How do we ensure technological development moves in the right direction to truly serve patients — meaning each of us? How can tools stay simple and affordable?

Regulators and health systems must step in too. They need to set usability standards for older users, fund inclusive design research, and require companies to build accessible products from the very beginning. Without their active involvement, we risk a divided system: some patients manage well, while others fall behind.

What steps will regulators, health authorities, industry, and society take together so self-care works for everyone as we age? I believe the key is inclusive planning — and it must start today.

References

1. Eurostat, "Population structure and ageing", https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing

2. OECD (2025), "Rapidly ageing populations will continue to put pressure on pension systems", https://www.oecd.org/en/about/news/press-releases/2025/11/rapidly-ageing-populations-will-continue-to-put-pressure-on-pension-systems.html

3. MK Science Set Publishers (2025), "Estimating the Prevalence of Multimorbidity Among the Adult Population in Primary Care Settings in European Countries – A Systematic Review and Meta-Analysis", https://mkscienceset.com/abstract/estimating-the-prevalence-of-multimorbidity-among-the-adult-population-in-primary-care-settings-in-european-countries-a-systematic-review-and-meta-analysis

4. Freihat O, et al. (2025), "Global burden and future projections of non-communicable diseases (2000–2050): Progress toward SDG 3.4 and disparities across regions and risk factors", https://pmc.ncbi.nlm.nih.gov/articles/PMC12694828/

5. Testa D, Iborra V, Dutech M, et al. (2025), "Impact of a Home-Based Remote Patient Monitoring System on Hospitalizations and Emergency Department Visits of Older Adults With Polypathology: Multicenter Retrospective Observational Study", https://doi.org/10.2196/64989

6. ResearchAndMarkets.com (2025), "Subcutaneous Biologics Industry Research Report 2025-2035: Market Expands With Over 175 Approved Therapies, Nearly 50% Are Protein-Based, Once-Daily Treatments", https://www.globenewswire.com/news-release/2025/12/01/3196768/28124/en/Subcutaneous-Biologics-Industry-Research-Report-2025-2035-Market-Expands-With-Over-175-Approved-Therapies-Nearly-50-Are-Protein-Based-Once-Daily-Treatments.html

7. Shukla AK, Misra S. (2025), "A Comprehensive Review of US-FDA Novel Drug Approvals from 2013-2022: An Observational Study", https://biomedpharmajournal.org/vol18no3/a-comprehensive-review-of-us-fda-novel-drug-approvals-from-2013-2022-an-observational-study/